Interactive Strength Inc.: TRNR Provides Shareholder Update on Sportstech Process & Operating Strategy

AUSTIN, TEXAS / ACCESS Newswire / January 7, 2026 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the Wattbike, CLMBR and FOR ...

What Causes Cylinder Wall Scoring (And How To Prevent It)

Cylinder wall scoring can be caused by a lack of oil or oil contamination. It can be prevented through careful maintenance ...

Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specifi ...

What Is the Typical 401(k) Contribution Rate and How Do You Compare?

The average American contributes a percentage of their paycheck to their 401(k). Here's how your savings rate compares.
Yahoo Finance

Vor Bio Announces $150 Million Private Placement

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...
Yahoo Finance

Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Hosted on MSN

Vor Biopharma approves stock option repricing plan

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Seeking Alpha

Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing

JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Investing

JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...
NerdWallet

How to Read Stock Charts: Quick-Start Guide

Stock market graphs don’t have to be a mystery. Here’s how to read stock charts for any company. Many, or all, of the products featured on this page are from our advertising partners who compensate us ...